COVID-19与非COVID-19住院肺炎对2型糖尿病患者长期心血管死亡率的影响:苏格兰全国前瞻性队列研究
基于苏格兰SCI-Diabetes登记库,纳入2016年及2020年疫情初期的2型糖尿病队列,链接住院与死亡记录,用泊松回归估计肺炎后心血管死亡的风险比。结果显示非COVID-19肺炎调整后RR为5.51(大流行前)和7.3(大流行期间),COVID-19肺炎为9.13;30天后两者趋同至4.24和3.35。
要点
- 住院肺炎无论病原体,均与心血管死亡风险即刻及长期升高相关。
- COVID-19肺炎短期心血管死亡风险高于其他肺炎,但随时间推移差异缩小。
- 作者认为应将肺炎纳入心血管风险评估,尤其关注COVID-19肺炎的急性影响。
核心结论
- 住院肺炎无论病因如何,均标志着心血管死亡风险即刻及长期升高;COVID-19肺炎短期风险高于其他肺炎,但随时间推移差异缩小。
研究设计与样本
- 使用SCI-Diabetes登记库识别两个2型糖尿病队列:2016年队列和2020年大流行 onset 时队列。
- 链接医院与死亡记录以确定肺炎暴露和心血管死亡,采用泊松回归估计率比(RR)并调整混杂因素。
- 中位随访时间分别为1461天(2016年队列)和700天(2020年队列)。
主要发现
- 非COVID-19肺炎后心血管死亡的调整RR为大流行前5.51(95%CI 5.31-5.71),大流行期间7.3(95%CI 6.86-7.76)。
- COVID-19肺炎后心血管死亡的调整RR为9.13(95%CI 8.55-9.75)。
- 肺炎后30天以上,RR趋同:非COVID-19肺炎为4.24(95%CI 3.90-4.60),COVID-19肺炎为3.35(95%CI 3.00-3.74),排除既往CVD病例后结果一致。
临床怎么用
- 作者认为这些发现强调应将肺炎纳入心血管风险评估,尤其关注COVID-19肺炎的急性影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In this study we examine whether hospitalized coronavirus disease 2019 (COVID-19) pneumonia increases long-term cardiovascular mortality more than other hospitalized pneumonias in people with type 2 diabetes and aim to quantify the relative cardiovascular disease (CVD) mortality risks associated with COVID-19 versus non-COVID-19 pneumonia. RESEARCH DESIGN AND METHODS: With use of the SCI-Diabetes register, two cohorts were identified: individuals with type 2 diabetes in 2016 and at the 2020 pandemic onset. Hospital and death records were linked for determination of pneumonia exposure and CVD deaths. Poisson regression estimated rate ratios (RRs) for CVD death associated with both pneumonia types, with adjustment for confounders. Median follow-up durations were 1,461 days (2016 cohort) and 700 days (2020 cohort). RESULTS: The adjusted RR for CVD death following non-COVID-19 pneumonia was 5.51 (95% CI 5.31-5.71) prepandemic and 7.3 (6.86-7.76) during the pandemic. For COVID-19 pneumonia, the RR was 9.13 (8.55-9.75). Beyond 30 days post pneumonia, the RRs converged, to 4.24 (3.90-4.60) for non-COVID-19 and 3.35 (3.00-3.74) for COVID-19 pneumonia, consistent even with exclusion of prior CVD cases. CONCLUSIONS: Hospitalized pneumonia, irrespective of causal agent, marks an increased risk for CVD death immediately and over the long-term. COVID-19 pneumonia poses a higher CVD death risk than other pneumonias in the short-term, but this distinction diminishes over time. These insights underscore the need for including pneumonia in CVD risk assessments, with particular attention to the acute impact of COVID-19 pneumonia.
引用
- McGurnaghan SJ, McKeigue PM, Blackbourn LAK, et al. Impact of COVID-19 and Non-COVID-19 Hospitalized Pneumonia on Longer-Term Cardiovascular Mortality in People With Type 2 Diabetes: A Nationwide Prospective Cohort Study From Scotland. Diabetes Care. 2024. PMID: 38889071. doi:10.2337/dc24-0124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。